The Prognostic Values of the Insulin-Like Growth Factor Binding Protein Family in Ovarian Cancer

Table 4

The prognostic value of the IGFBP4 mRNA expression in ovarian cancer.

	Overall survival			Progression-free survival
	Cases	HR (95% CI)	value	Cases	HR (95% CI)	value
Histology
All cancer patients	1656	1.14 (0.99−1.3)	0.068	1435	0.94 (0.83−1.06)	0.32
Serous cancer patients	1207	1.17 (1−1.37)	0.047	1104	1.24 (1.07−1.44)	0.005
Endometrioid cancer patients	37	2.81 (0.31−25.11)	0.34	51	0.1 (0.01−0.79)	0.0077
Pathological grades
I	56	0.19 (0.03−1.47)	0.076	37	0.24 (0.05−1.09)	0.045
II	324	1.41 (1.04−1.92)	0.026	256	1.52 (1.11−2.09)	0.0085
III	1015	1.18 (0.98−1.42)	0.08	837	1.23 (1−1.5)	0.045
Clinical stages
I and II	135	1.47 (0.67−3.21)	0.33	163	0.34 (0.19−0.6)	8.7e−05
III and IV	1220	1.16 (0.99−1.35)	0.065	1081	1.34 (1.15−1.56)	0.00015
Chemotherapy
Contains platin	1409	1.24 (1.06−1.44)	0.0067	1259	1.1 (0.96−1.27)	0.17
Contains taxol	793	1.15 (0.95−1.4)	0.15	715	1.21 (1.02−1.45)	0.029
Contains taxol+platin	776	1.18 (0.97−1.43)	0.1	698	1.23 (1.03−1.47)	0.022

.